Hao Wang, Ph.D., MPA, leads VuRoyal Pharmaceutical as Chief Executive Officer, bringing decades of expertise at the intersection of pharmaceutical science, regulatory affairs, and global supply chain management. A recognized voice in the vaccine adjuvant industry, Dr. Wang has moderated high-profile scientific forums on GMP-grade adjuvant technology — including VuRoyal's inaugural QS-21 Forum in Shanghai in March 2024 and the 2nd Online Technology Forum on Novel Vaccine Adjuvants in April 2025. Under his leadership, VuRoyal secured its exclusive partnership with Desert King International in China, achieved multiple regulatory milestones including pharmaceutical excipient registration in China, and established the company as a trusted FDA-registered pharmaceutical wholesaler operating from Boston with a truly global reach. Dr. Wang's vision centers on making safe, genuine, and compliant pharmaceutical substances reliably accessible to logistics companies, research sponsors, and healthcare providers worldwide.